Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Ruxolitinib & COVID-19

Alessandro Gozzetti • 27 Nov 2020
ASH 2020
General Ruxolitinib

Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, discusses the use of ruxolitinib, a selective inhibitor of the Janus-associated tyrosine kinases (JAK1 and JAK2), in patients infected with COVID-19. Ruxolitinib was found to be efficacious in terms of reducing ICU admissions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Alessandro Gozzetti

Treating transplant-ineligible patients with myeloma in Italy
1:29
Treating transplant-ineligible patients with myeloma in Italy
Alessandro Gozzetti • 27 Sep 2024
Final results of the DART4MM study of daratumumab for MRD eradication in myeloma
2:42
Final results of the DART4MM study of daratumumab for MRD eradication in myeloma
Alessandro Gozzetti • 27 Sep 2024
Early relapse prediction in myeloma treated with novel agents
1:31
Early relapse prediction in myeloma treated with novel agents
Alessandro Gozzetti • 24 Feb 2021
FORTE: MRD negativity as key prognostic factor in NDMM
1:37
FORTE: MRD negativity as key prognostic factor in NDMM
Alessandro Gozzetti • 24 Feb 2021

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals